Vir Biotechnology
Vir Biotechnology
VIR
NASDAQ
8.26
USD
-15.71%
About
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).
It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure.
It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 554.9K |
| Three Month Average Volume | 22.7M |
| High Low | |
| Fifty-Two Week High | 13.09 USD |
| Fifty-Two Week Low | 7.61 USD |
| Fifty-Two Week High Date | 05 Jun 2024 |
| Fifty-Two Week Low Date | 25 Apr 2024 |
| Price and Volume | |
| Current Price | 8.26 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.11% |
| Thirteen Week Relative Price Change | -24.85% |
| Twenty-Six Week Relative Price Change | -33.16% |
| Fifty-Two Week Relative Price Change | -47.93% |
| Year-to-Date Relative Price Change | -30.66% |
| Price Change | |
| One Day Price Change | -0.48% |
| Thirteen Week Price Change | -19.57% |
| Twenty-Six Week Price Change | -26.51% |
| Five Day Price Change | -5.82% |
| Fifty-Two Week Price Change | -34.76% |
| Year-to-Date Price Change | -17.89% |
| Month-to-Date Price Change | -18.70% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 11.79864 USD |
| Book Value Per Share (Most Recent Quarter) | 10.49615 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 11.50556 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 10.23379 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.75554 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.64251 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.58382 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.58553 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.57665 USD |
| Normalized (Last Fiscal Year) | -4.58553 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.58553 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.57665 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.58553 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.57665 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 11.2954 USD |
| Cash Per Share (Most Recent Quarter) | 8.42715 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.44093 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.34702 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.39574 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 14 |
| Cash Flow Revenue (Trailing Twelve Months) | -582 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -624.10% |
| Pretax Margin (Last Fiscal Year) | -728.93% |
| Pretax Margin (5 Year) | 7.04% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 96.79% |
| Gross Margin (Trailing Twelve Months) | 98.80% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -794.04% |
| Operating Margin (Trailing Twelve Months) | -715.62% |
| Operating Margin (5 Year) | 3.28% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -713.76% |
| Net Profit Margin (Trailing Twelve Months) | -612.40% |
| Net Profit Margin (5 Year) | -1.53% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 58.27% |
| Tangible Book Value (5 Year) | 82.74% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -19.02% |
| Revenue Growth (3 Year) | 51.87% |
| Revenue Change (Trailing Twelve Months) | -83.93% |
| Revenue Per Share Growth | 45.80% |
| Revenue Growth (5 Year) | 4.11% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 16.77% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 30.09% |
| EPS Change (Trailing Twelve Months) | -81.38% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,151,065,000 |
| Net Debt (Last Fiscal Year) | -1,522,409,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 13 |
| Price to Sales (Trailing Twelve Months) | 14 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 11 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 2 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 13 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -800,358,000 |
| Free Cash Flow (Trailing Twelve Months) | -458,780,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.06% |
| Return on Assets (Trailing Twelve Months) | -24.69% |
| Return on Assets (5 Year) | -0.61% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -33.53% |
| Return on Equity (Trailing Twelve Months) | -29.78% |
| Return on Equity (5 Year) | -0.82% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -30.49% |
| Return on Investment (Trailing Twelve Months) | -26.90% |
| Return on Investment (5 Year) | -0.72% |